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Tumor Cell–Targeted Delivery of Nanoconjugated
Oligonucleotides in Composite Spheroids
Kyle Carver, Xin Ming, and Rudy L. Juliano
Standard tissue culture has often been a poor model for predicting the efficacy of anti-cancer agents including
oligonucleotides. In contrast to the simplicity of monolayer tissue cultures, a tumor mass includes tightly packed
tumor cells, tortuous blood vessels, high levels of extracellular matrix, and stromal cells that support the tumor.
These complexities pose a challenge for delivering therapeutic agents throughout the tumor, with many drugs
limited to cells proximal to the vasculature. Multicellular tumor spheroids are superior to traditional monolayer
cell culture for the assessment of cancer drug delivery, since they possess many of the characteristics of metastatic
tumor foci. However, homogeneous spheroids comprised solely of tumor cells do not account for some of the key
aspects of metastatic tumors, particularly the interaction with host cells such as fibroblasts. Further, homogeneous
culture does not allow for the assessment of targeted delivery to tumor versus host cells. Here we have evaluated
delivery of targeted and untargeted oligonucleotide nanoconjugates and of oligonucleotide polyplexes in both
homogeneous and composite tumor spheroids. We find that inclusion of fibroblasts in the spheroids reduces
delivery efficacy of the polyplexes. In contrast, targeted multivalent RGD–oligonucleotide nanoconjugates were
able to effectively discriminate between melanoma cells and fibroblasts, thus providing tumor-selective uptake
and pharmacological effects.
Introduction
Tumors include many types of host cells, most promi-nently fibroblasts. Activated fibroblasts are key modu-
lators of metastasis through promoting invasion, migration,
and growth of cancer cells. This is achieved through degra-
dation of the extracellular matrix (ECM) and basement
membrane of the primary tumor as well as by providing
support at the distal site by the production of growth factors
and other components [1–3]. However, not all of the fibro-
blasts within a tumor are harmful to the patient; carcinoma-
associated fibroblasts are able to express both tumor promoting
and tumor suppressing molecules [4,5]. Normal fibroblasts
can suppress tumor growth and progression [1,4]. There-
fore, it is usually desirable for therapeutic agents to be able
to affect cancer cells without harming fibroblasts or other
host cells.
Oligonucleotides can potentially provide effective and se-
lective therapy of cancer [6,7]. However, the utility of these
compounds for therapy has been limited due to the difficulty in
delivering them to their sites of action within specific cells of
the tumor [8–10]. Various nanoparticle formulations have
been utilized for delivery of oligonucleotides [11,12]. Nano-
particles are advantageous due to the fact that they are large
enough to escape renal clearance and can passively target tu-
mors through the enhanced permeation and retention effect
[13]. However, nanoparticles tend to accumulate proximal to
the blood vessels, leaving distal portions of the tumor untreated
[14,15]. The lack of diffusion is a result of the composition and
geometry of the ECM along with tightly packed cells of the
tumor, limiting the pore size of the extracellular space [16].
Tumor spheroids mimic the structure of metastatic lesions
and are more relevant for assessing drug delivery than
monolayer cultures [17,18]. We have shown previously that
human serum albumin (HSA) nanoconjugates with multiple
arginine-glycine-aspartic acid (RGD) peptides are able to
effectively penetrate and distribute in a tumor spheroid model
[19]. The peptide RGD serves as a ligand for the integrin
receptor aVb3 [20], which has increased expression in some
cancers and is associated with progression of metastasis [21].
Furthermore, we have shown that these conjugates are su-
perior to larger nanoparticles for delivering oligonucleotides
to cells within a tumor spheroid [22]. However, these tumor
spheroids were formed from melanoma cells alone and
therefore could not be utilized for determining differential
delivery to tumor versus host cells. In this study, we utilized a
more complex tumor spheroid comprised of melanoma cells
and human dermal fibroblasts. We assessed both the ability of
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our RGD conjugates to distribute throughout the complex




A375 human melanoma cells were stably transfected with a
firefly luciferase (A375 Luc705) [23] expression cassette
containing a mutated intron. The mutated intron can be re-
moved by using a splice switching oligonucleotide, thus giving
inducible expression of the reporter, as described previously
[24]. An A375 cell line with a constitutive green fluorescent
protein expression cassette was also used. Human dermal fi-
broblasts (HDF) at passage 18 were obtained from the Tissue
Culture Facility at the University of North Carolina and used
between passages 20 and 28. All cells were grown in high
glucose Dulbecco’s modified Eagle’s medium (DMEM) me-
dia (Sigma) supplemented with 10% fetal bovine serum (FBS).
Generation of multicellular tumor spheroids
Multicellular tumor spheroids (MCTS) were generated
using the hanging drop method described previously [22].
Briefly, cells were trypsinized and resuspended in 20% FBS
high glucose DMEM at a concentration to achieve 3000 cells
per 30 mL for single cell MCTS or 13000 A375 Luc705 and
3000 HDF cells per 30 mL for composite MCTS. In a 72-
microwell plate (Nunc 438733, Thermo Fisher Scientific),
30 mL was added to each well; plates were then inverted and
incubated at 37C for 3–5 days on an orbital shaker. Once
formed, MCTS, 10 spheroids per well, were transferred to a
48 well plate coated with 1.5% agarose for treatment.
Oligonucleotide formulation and cell treatment
The splice switching oligonucleotide 623 (SSO623) [5¢-
GTTATTCTTTAGAATGGTGC-3¢], which can correct the
mutated introns in Luc705 constructs and induce reporter
gene expression [23], or its five base mismatch control [5¢-
GTAATTATTTATAATCGTCC-3], were used in all exper-
iments. A 3¢ carboxytetramethylrhodamine (TAMRA) labeled
version of 623 was also used (SSO623-T). Complexes of a
cationic polymer (jetPEI; Polyplus) with SSO623-T were
prepared per the vendor’s instructions. These polyplexes are
approximately 300 nM in size [25]. Preparation of a morpho-
lino (PMO) version of SSO623 conjugated to human serum
albumin (HSA) (HSA-PMO) as well as an RGD-PMO con-
jugate (HSA-PMO-RGD) were performed as described pre-
viously [19]. These nanoconjugates also include an Alexa 488
fluorophore. The HSA-PMO and HSA-PMO-RGD conjugates
are about 13 nm in diameter and thus are substantially smaller
than most oligonucleotide nanocarriers [19]. In both spheroid
models, uptake of polyethylenimine 623 (PEI-623), HSA-
PMO, and HSA-PMO-RGD was performed in 10% FBS
DMEM. All groups were treated for 16 hours. Spheroids were
washed to remove any remaining nanoconjugate and incubated
an additional 48 hours before being harvested for analysis.
Luciferase assay
Cells were washed with phosphate buffered saline before
being digested with luciferase lysis buffer (New England
Biolabs) at a dilution of 1:4 in double-distilled water. After
centrifugation, 50 mL of luciferin substrate (Promega) was
added to 20mL of lysate and luciferase activity was measured
in a plate reader (FLUOstar Omega; BMG Labtech) over a
5-second window. The sum of blank corrected data over
seconds 2–5 of the window was used to quantitate induction.
Induction was normalized to protein concentration measured
with a bovine serum albumin assay (Thermo Scientific).
Flow cytometry
Spheroids were trypsinized and fixed in single cell sus-
pension with 4% paraformaldehyde. In some cases cells were
incubated with a fibroblast-selective cluster of differentiation
90 (CD90) antibody conjugated to APC (Life Technologies)
before being resuspended in phosphate-buffered saline (PBS)
for flow cytometry on an LSR II using a 488 nm laser with
510/20 bandpass filter (green fluorescent protein/Alexa 488),
561-nm laser with 610/20 bandpass (TAMRA), and 639-nm
laser with 675/20 bandpass (Alexa 633/APC). After gating
for live singlet cells, cells were gated for APC flourescence to
differentiate melanoma cells from HDFs. Uptake was quan-
tified by normalizing mean Alexa 488 (HSA-623 and HSA-
623-RGD) or TAMRA (PEI-SSO623-T) fluorescence value
with the control cell’s autofluorescence.
Histology
MCTS were harvested and fixed in 4% paraformaldehyde
before being embedded in 1.5% agarose molds to maintain
orientation. These molds were then placed in 70% ethanol
and stored prior to being embedded in paraffin and sectioned.
Serial slides were processed with Masson’s trichrome to
demonstrate the density of cells as well as collagen content.
Immunofluorescence
MCTS were harvested and fixed in 4% paraformaldehyde
before being cryoprotected in 30% sucrose in PBS. Spheroids
were placed in a 1.5% agarose block in order to maintain ori-
entation before being embedded in optimal cutting temperature
(OCT) medium (Sakura) and sectioned. Slides with serial
interrupted sections were stained with a CD90 antibody con-
jugated to allophycocyanin (APC) and exposed to 4¢,6-
diamidino-2-phenylindole (DAPI) prior to being mounted.
Images were collected on a Leica DMIRB inverted microscope
using a 10 · objective and HQ2 color camera (Photometrics).
Results
Characterization of complex spheroids
We have shown previously that A375 melanoma cells will
form tumor spheroids with densely packed cells but limited
extracellular matrix [22]. In order to determine how the ad-
dition of fibroblasts affects the growth and morphology of the
tumor spheroids, A375 spheroids were developed with and
without human dermal fibroblasts (HDF). The complex
spheroids developed much quicker, taking 2–3 days com-
pared with 5–7 days for A375 cells alone, and required in-
creased trypsinization to dissociate, 60 minutes compared to
5 minutes (data not shown). In support of these observations,
Masson’s trichrome stain shows that the complex spheroids
are more uniform and circular, have more tightly packed
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cells, and have increased extracellular matrix (Fig. 1A, B).
Expression of CD90 was measured to differentiate the mel-
anoma cells from fibroblasts in the complex spheroids
(Supplementary Figs S1, S2; Supplementary Data are
FIG. 1. Spheroid morphology. Spheroids grown from (A)
A375humanmelanomacells transfectedwithafireflyluciferase
(A375 Luc705) or (B) A375 Luc705 and human dermal fibro-
blast (HDF) cells were fixed prior to paraffin embedding. Sec-
tions of spheroids were stained using Masson’s trichrome. The
purple staining in the interstices between cells represents extra-
cellular matrix. (C) A375 green fluorescent protein (GFP) +
HDF spheroids were fixed and embedded in optimal cutting
temperature (OCT) medium prior to sectioning. Sections were
stained with cluster of differentiation 90-allophycocyanin anti-
body(CD90-APC)prior to imaging.Scalebarrepresents200mm.
Color images available online at www.liebertpub.com/nat
FIG. 2. Nanoparticle uptake in spheroids. (A) A375Luc705
and (B) A375Luc705 + HDF spheroids were incubated with
either HSA-PMO or HSA-PMO-RGD (human serum albumin-
morpholino-[arg-gly-asp]) at 100 nM for 16 hours. (C)
A375Luc705 + HDF spheroids were incubated with SSO623-
polyethyleneimine (PEI) at 100 nM for 16 hours. After the
incubationperiod spheroidswere dispersed with trypsin,fixed,
and stained with CD90-APC prior to fluorescent measure-
ments by flow cytometry. Uptake is measured as percent
change compared with untreated control spheroids and re-
presentedasmean – standarderrorof themean(SEM).n = 4–7.
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available online at www.liebertpub.com/nat). The distribu-
tion of HDF within the spheroid is heterogeneous (Fig. 1 C).
Targeted uptake of oligonucleotide conjugates
One of the primary challenges for cancer therapeutics is
attaining the ability to direct drugs selectively to the cells of
interest without damaging the surrounding normal tissue. In
A375 spheroids, the RGD-linked targeted nanoconjugates
increased delivery over 80-fold compared to the unliganded
conjugates (Fig. 2 A). Interestingly, there was little loss of
enhanced targeted delivery in the complex spheroids, with a
60-fold increase over non-RGD control nanoconjugates (Fig.
2 B). Furthermore, when uptake in HDFs was assessed there
was no difference between the two conjugates, suggesting
that the RGD-conjugate was differentially targeting the
melanoma cells. Complex spheroids were also treated with a
SSO623-TAMRA cationic polymer (jetPEI) complex to as-
sess nonspecific uptake of a typical oligonucleotide polyplex
(Fig. 2C). While there was a high degree of uptake of SSO623
into the A375 cells, there was also substantial uptake into the
fibroblasts of the spheroids suggesting that the non-targeted
polyplex delivery would affect both tumor and normal cells.
Additionally, in previous studies we have shown that similar
FIG. 3. Nanoparticle uptake in
spheroid sections. Spheroids
grown from A375Luc705 were
treated with either (A) HSA-
PMO or (B) HSA-PMO-RGD
and spheroids grown from
A375Luc705 + HDF cells were
treated with either (C) HSA-
PMO or (D) HSA-PMO-RGD for
16 hours. Spheroids were fixed
and embedded in OCT prior to
sectioning. Spheroid sections were
stained with CD90-APC prior
to imaging. Blue, DAPI, 4¢,6-
diamidino-2-phenylindole; green,
Alexa 488; red, APC. Scale bar
represents 200mm. Color images
available online at www.liebertpub
.com/nat
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PEI complexes primarily affect cells at or near the surface of
the spheroid [22]. Taken together these data demonstrate that
the HSA-SSO623-RGD conjugates are able to both increase
cellular uptake and specifically target melanoma cells within
the complex spheroid.
Flow cytometry is unable to tell us where in the spheroid
the conjugates are distributing. To assess the distribution of
the nanoconjugates within the two spheroid models, we im-
aged frozen sections of treated spheroids stained with a
CD90-APC antibody. As expected, there was no positive
staining of CD90 in the A375-only spheroids (Fig. 3A, B). In
spheroids treated with HSA-PMO, there was minor uptake in
the periphery of the spheroid with no penetration (Fig. 3 A),
while the conjugates with RGD were able to effectively
penetrate and distribute throughout the spheroid (Fig. 3B).
Similar to the results shown in Fig. 2B, uptake of HSA-PMO
in the complex spheroids was primarily in the fibroblasts that
were located on the periphery of the spheroid (Fig. 3C).
Treatment of the complex spheroids with HSA-PMO-RGD
results in distribution similar to that seen in the A375 only
spheroid with the majority of conjugate being taken up by the
melanoma cells, demonstrated by little colocalization be-
tween Alexa 488 and APC (Fig. 3 D).
Splice-switching efficacy
We examined the ability of the nanoconjugates and the
polyplexes to elicit a biological effect. Complex and simple
spheroids were formed from A375-Luc705 melanoma cells
with and without HDFs, respectively, and treated with HSA-
PMO, HSA-PMO-RGD, SSO623-PEI, or SSO623mm-PEI.
Induction of luciferase by SSO623mm-PEI was used as a
negative control. In both spheroid types, the levels of luci-
ferase activity induced by the HSA-PMO conjugate was
similar to that of the mismatch control (Fig. 4A, B). Im-
portantly, the HSA-PMO-RGD conjugate was able to sig-
nificantly increase luciferase activity compared with control
in both the simple and complex spheroids. Treatment of
simple spheroids with SSO623-PEI resulted in a similar in-
crease in luciferase activity to that of the RGD conjugate.
However, interestingly, in the complex spheroid the induc-
tion capacity of the PEI complex was significantly attenuated
down to control levels. The reduction in luciferase activity in
the complex spheroids is most likely due to a combination of
more tightly packed cells with increased ECM deposition and
preventing effective penetration, along with nonspecific up-
take into fibroblasts. These data suggest that while the addi-
tion of fibroblasts reduces biological effect of larger polyplex
complexes, it does not affect that of the smaller targeted
oligonucleotide nanoconjugates.
Discussion
There is a clear need to develop improved therapeutics that
can effectively target the lesions in advanced cancer. However,
the use of monolayer cell cultures for drug screening, with
their lack of similarity to the tumor microenvironment, has led
to inefficient translation from in vitro studies to in vivo ther-
apies [17]. The three-dimensional tumor spheroid model has
been suggested to represent an in vitro system similar to that of
micrometastases [26]. In fact, it has been suggested that certain
cancers utilize endogenous spheroid formation to survive
transit through the peritoneal cavity to sites of metastasis [18].
In addition, recent studies have shown that metastases require
the support of stromal cells for continuous growth and propa-
gation [1–3]. These observations suggest that a co-culture tu-
mor spheroid model featuring cancer cells with fibroblasts
would improve the physiological relevance as well as pro-
viding a means for studying targeted drug delivery.
To further increase the verisimilitude to tumors in vivo, one
might consider including vascular endothelial cells, lympho-
cytes and macrophages into the spheroid since these all play
important roles in tumor biology and are potential therapeutic
targets [27]. However, practical constraints may come into
play as more cell types are added. We have shown that in-
clusion of fibroblasts in A375 tumor spheroids increases the
tightness and ECM deposition of the spheroid (Fig. 1). The use
of a fluorescently conjugated CD90 antibody effectively dis-
criminates between the fibroblasts and cancer cells of the
spheroid and thus helps to define oligonucleotide delivery.
Due to the support stromal cells provide for metastasis, it
has been suggested that fibroblasts could pose a potential
FIG. 4. Induction of luciferase in spheroids. (A)
A375Luc705 and (B) A375Luc705 + HDF spheroids were
incubated with either HSA-PMO, HSA-PMO-RGD, PEI-
SSO623, or PEI-SSO623mm at 100 nM for 16 hours and
then incubated for a further 48 hours. Spheroids were dis-
persed and subsequent cell suspension lysed in a luciferase
buffer. Luciferase activity was measured on a FLUOstar
Omage plate reader and quantified as relative luminescence
units per mg protein after subtracting control, untreated
spheroid, values and depicted as mean – SEM. n = 3–10.
*p < 0.05 compared with HSA-PMO. **p < 0.01 compared
with HSA-PMO and SSO623mm-PEI. ***p < 0.001 com-
pared with all other groups.
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therapeutic target [28,29]. However, it has also been recently
suggested that not all of the fibroblasts within a tumor are
harmful to the patient; carcinoma associated fibroblasts are
able to express both tumor promoting and tumor suppressing
molecules simultaneously [4,5]. In addition, normal fibroblasts—
those that have not been activated by the cancer cells—can
suppress tumor growth and progression [1]; primary fibro-
blasts from a tumor are able to reduce the growth of co-
cultured cancer cells in vitro [4]. Therefore, direct targeting
of cancer cells should prove to be a more advantageous
method of therapy than ubiquitous cell death within the tumor
by leaving the hosts natural defenses intact.
Utilizing the complex tumor spheroid model we demon-
strate that an oligonucleotide nanocarrier comprised of albu-
min conjugated with multiple RGD ligands can specifically
target melanoma cells over human dermal fibroblasts (Fig. 2).
Furthermore, these conjugates can distribute and deliver oli-
gonucleotides throughout the spheroid while larger complexes
and non-targeted conjugates are confined to the periphery of
the spheroid (Fig. 3). The lack of observable uptake of the non-
RGD HSA conjugates deep within the spheroid could be due to
poor penetration of the conjugate; alternatively, the conjugate
may possibly penetrate into the spheroid but fail to be taken up
into cells, resulting in the conjugate being washed away during
processing steps.
Oligonucleotides are potentially useful therapeutic agents
for cancer. However, the result of non-targeted delivery to host
cells is a reduction in efficacy and possible off-target actions.
We demonstrate such an effect with delivery of SSO623 to the
complex spheroid using a cationic polyplex. Uptake of the
polyplex into fibroblasts is accompanied by a significant at-
tenuation of the luciferase induction effect in tumor cells (Fig.
4). The RGD nanoconjugates, on the other hand, were targeted
specifically to the A375 melanoma cells and showed no re-
duction in luciferase induction between simple and complex
spheroids. In fact, there appeared to be a greater level of in-
duction in the complex spheroids, which could possibly be a
result of growth promoting effects of fibroblasts.
Our studies suggest that RGD is an effective targeting ligand
for melanoma cells and, to the extent that complex tumor
spheroids represent in vivo micrometastasis, the inclusion of
RGD into nanoconjugates is a superior method for oligonu-
cleotide delivery compared to non-targeted conjugates or large
cationic polyplexes. This general approach may have utility for
other types of oligonucleotides such as siRNA and could em-
ployother typesoftargeting ligandssuchasaptamers.However,
ultimately the capacity for targeted delivery by RGD nano-
conjugates will require validation in vivo. This would include
demonstration of selective uptake by tumor cells as opposed to
host cells as well as evidence of tumor growth inhibition.
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